Virtech Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

VirTech Bio is a private, pre-clinical biotech company developing OxyBridge™, a novel hemoglobin-based oxygen carrier (HBOC) designed to address critical unmet needs in trauma care and organ transplantation. The company's strategy involves pursuing an initial regulatory pathway through an ex vivo organ perfusion device application, anticipated for market entry in 2025, followed by the more challenging in vivo indication for hemorrhagic shock. With over $13.7 million in non-dilutive funding from U.S. DoD agencies and a management team with deep military medical and HBOC expertise, VirTech is positioning itself as a leader in next-generation oxygen therapeutic solutions.

Trauma/Hemorrhagic ShockOrgan Transplantation

Technology Platform

Proprietary human-derived hemoglobin-based oxygen carrier (HBOC) platform (OxyBridge™) featuring an ultra-polymer/megapolymer design intended to prevent vasoconstriction and enable safe oxygen delivery.

Opportunities

The primary opportunity is addressing the massive unmet need for a field-deployable oxygen carrier in trauma care, a top priority for the U.S.

Department of Defense with clear procurement potential.

A secondary, nearer-term opportunity exists in the growing organ transplant market, where OxyBridge™ could improve preservation and outcomes as part of machine perfusion devices.

Risk Factors

The technology faces significant clinical risk, as the HBOC field has a history of failure due to safety issues like vasoconstriction and hypertension.

Regulatory hurdles for the in vivo trauma indication will be exceptionally high.

The company also faces execution risk in manufacturing scale-up and reliance on future fundraising.

Competitive Landscape

The competitive landscape for HBOCs is sparse due to historical clinical failures, but includes other biotechs and academic groups pursuing next-generation hemoglobin polymers or perfluorocarbon-based oxygen carriers. VirTech's main competition may come from advances in blood product logistics (e.g., freeze-dried plasma, whole blood programs) rather than direct HBOC rivals.

More companies in Biologics / Biosimilars →More companies in United States →